Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Alcohol Clin Exp Res. 2016 Jun 1;40(7):1567–1576. doi: 10.1111/acer.13110

Table 1.

Baseline Characteristics by Medication Condition, Mean (SD) or n (%)

Placebo (n=17) 1 mg/day Varenicline (n=12) 2 mg/day Varenicline (n=15) p

Age 35.3 (9.47) 33.9 (7.29) 34.4 (12.6) 0.93
Sex (% male) 65% 58% 73% 0.71
Race (% White) 0.15
White 8 (47) 8 (67) 12 (80)
Other 9 (53) 4 (33) 3 (20)
Education 0.03
≤ High school 8 (47) 5 (42) 1 (7)
≥ College 9 (53) 7 (58) 14 (93)
Marital Status 0.09
Not married 13 (76) 9 (75) 15 (100)
Married 4 (24) 3 (25) 0 (0)
Tobacco Use (smokers only)
Cigarettes per day 13.9 (7.26) 13.5 (4.08) 15.9 (6.39) 0.68
FTND scorea* 4.30 (2.31) 4.63 (1.85) 4.0 (1.94) 0.82
Alcohol Use
Weekly frequency (days)b 4.94 (1.74) 4.14 (1.60) 4.39 (1.55) 0.40
Drinks per episode 6.66 (3.46) 6.66 (2.75) 6.19 (3.26) 0.90
AUDIT scoresc 13.5 (6.97) 12.3 (4.58) 10.1 (3.61) 0.21

AUDIT, Alcohol Use Disorders Identification Test; FTND, Fagerström Test for Nicotine Dependence

a

Range: scores ≥ 4 for nicotine dependence.

b

Means calculated over 30 days before intake.

c

Scores ≥ 8 for alcohol misuse.

*

n=10, 8, 9 for placebo, 1 mg/day varenicline, and 2 mg/day varenicline, respectively.

Note: education (p=.03); otherwise, no difference between groups using chi-square or ANOVA where appropriate.